Erschienen in:Frontiers in Bioengineering and Biotechnology
Sprache:
Nicht zu entscheiden
DOI:
10.3389/fbioe.2023.1144963
ISSN:
2296-4185
Entstehung:
Anmerkungen:
Beschreibung:
<jats:p>Bacteria-driven biohybrid microbots have shown great potential in ca<jats:sup>n</jats:sup>cer treatment. However, how precisely controlling drug release at the tumor site is still an issue. To overcome the limitation of this system, we proposed the ultrasound-responsive SonoBacteriaBot (DOX-PFP-PLGA@<jats:italic>EcM</jats:italic>). Doxorubicin (DOX) and perfluoro-n-pentane (PFP) were encapsulated in polylactic acid-glycolic acid (PLGA) to form ultrasound-responsive DOX-PFP-PLGA nanodroplets. Then, DOX-PFP-PLGA@<jats:italic>EcM</jats:italic> is created by DOX-PFP-PLGA amide-bonded to the surface of <jats:italic>E. coli MG1655</jats:italic> (<jats:italic>EcM</jats:italic>). The DOX-PFP-PLGA@<jats:italic>EcM</jats:italic> was proved to have the characteristics of high tumor-targeting efficiency, controlled drug release capability, and ultrasound imaging. Based on the acoustic phase change function of nanodroplets, DOX-PFP-PLGA@<jats:italic>EcM</jats:italic> enhance the signal of US imaging after ultrasound irradiation. Meanwhile, the DOX loaded into DOX-PFP-PLGA@<jats:italic>EcM</jats:italic> can be released. After being intravenously injected, DOX-PFP-PLGA@<jats:italic>EcM</jats:italic> can efficiently accumulate in tumors without causing harm to critical organs. In conclusion, the SonoBacteriaBot has significant benefits in real-time monitoring and controlled drug release, which has significant potential applications for therapeutic drug delivery in clinical settings.</jats:p>